Delcath Systems — Third Quarter 2026 Earnings Summary

Delcath Systems reported third-quarter 2026 total revenue of $35.1 million, a significant increase from $20.6 million in the same period of 2025, driven by $32.7 million in HEPZATO KIT sales and $2.4 million in CHEMOSAT sales. The company achieved a net income of $7.0 million and non-GAAP adjusted EBITDA of $11.5 million, while maintaining gross margins of 89% and holding $104.3 million in cash and investments with no debt. Business highlights include a 72% growth in HEPZATO volume, an active network of 33 treatment centers, and the advancement of the global Phase 2 DELUMA trial for liver-dominant HER2-negative metastatic breast cancer. Consequently, Delcath raised its full-year 2026 revenue guidance to a range of $115 million to $117 million, anticipating at least 41% growth in HEPZATO KIT volume over 2025.